Stock PAVM PAVMED INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PAVmed Inc.

Equities

PAVM

US70387R4039

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-02 pm EDT 		5-day change 1st Jan Change
2.24 USD -3.03% Intraday chart for PAVmed Inc. +26.55% -45.63%
Mar. 27 Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
Mar. 25 PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
PAVMED INC. Stock PAVmed Inc.
-45.63% 21.13M
C+
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.62% 218B
B
DANAHER CORPORATION Stock Danaher Corporation
+6.70% 183B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.94% 134B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+24.60% 106B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-2.66% 61.12B
A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.89B
B+
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+11.55% 51.26B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-1.09% 40.3B
A
RESMED, INC. Stock ResMed, Inc.
+26.82% 32.05B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PAVM Stock
  4. Ratings PAVmed Inc.